139 related articles for article (PubMed ID: 26841786)
1. A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines.
Wani P; Blanco-Garcia C
Curr Cardiol Rep; 2016 Mar; 18(3):24. PubMed ID: 26841786
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
5. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic considerations in the management of hypertension.
Pardell H; Tresserras R; Armario P; Hernández del Rey R
Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
[TBL] [Abstract][Full Text] [Related]
10. Simulating the impact of improved cardiovascular risk interventions on clinical and economic outcomes in Russia.
Shum K; Alperin P; Shalnova S; Boytsov S; Kontsevaya A; Vigdorchik A; Guetz A; Eriksson J; Hughes D
PLoS One; 2014; 9(8):e103280. PubMed ID: 25141122
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.
Booth N; Jula A; Aronen P; Kaila M; Klaukka T; Kukkonen-Harjula K; Reunanen A; Rissanen P; Sintonen H; Mäkelä M
BMC Health Serv Res; 2007 Oct; 7():172. PubMed ID: 17958883
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness issues in hypertension control.
Schueler K
Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
Ekman M; Bienfait-Beuzon C; Jackson J
J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
[TBL] [Abstract][Full Text] [Related]
15. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
16. The economic impact of hypertension.
Elliott WJ
J Clin Hypertens (Greenwich); 2003; 5(3 Suppl 2):3-13. PubMed ID: 12826765
[TBL] [Abstract][Full Text] [Related]
17. Economic implications of evidence-based prescribing for hypertension: can better care cost less?
Fischer MA; Avorn J
JAMA; 2004 Apr; 291(15):1850-6. PubMed ID: 15100203
[TBL] [Abstract][Full Text] [Related]
18. Population impact of the 2017 ACC/AHA guidelines compared with the 2013 ESH/ESC guidelines for hypertension management.
Vaucher J; Marques-Vidal P; Waeber G; Vollenweider P
Eur J Prev Cardiol; 2018 Jul; 25(10):1111-1113. PubMed ID: 29637794
[TBL] [Abstract][Full Text] [Related]
19. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
Jackson R
J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
[TBL] [Abstract][Full Text] [Related]
20. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
